Article
A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
Anticancer research - 1 Aug 2020
Tamiya Akihiro, Tamiya Motohiro, Go Hirofumi, Inoue Takako, Kunimasa Kei, Nakahama Kenji, Taniguchi Yoshihiko, Shiroyama Takayuki, Isa Shun-Ichi, Nishino Kazumi, Kumagai Toru, Suzuki Hidekazu, Hirashima Tomonori, Atagi Shinji, Shintani Ayumi, Imamura Fumio
Abstract excerpt
AIM: Although nivolumab improves progression-free (PFS) and overall (OS) survival of patients previously treated for metastatic non-small-cell lung cancer (NSCLC), approximately 50% of treated patients experience disease progression within 3 months. As predictive biomarkers of response are not yet established, development of biomarkers to predict longer PFS and OS of patients treated with nivolumab is crucial....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.